Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues

Hwangbo, Hanjun; Chae, SooJung; Kim, Wonjin; Jo, Seoyul; Kim, Geun Hyung

doi:10.7150/thno.90093

Cited by 13 publications

(3 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDTOs have also been integrated into microfluidic devices, so‐called tumour‐on‐a‐chip (TuChip), providing a circulatory and flow system 55,56 . TuChip can be straightforward and mimic tissue−tumour interactions.…”

Section: Pdtos and Assembloidsmentioning

confidence: 99%

Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy

Mei,

Liu,

Tian

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

BackgroundOrganoid technology is an emerging and rapidly growing field that shows promise in studying organ development and screening therapeutic regimens. Although organoids have been proposed for a decade, concerns exist, including batch‐to‐batch variations, lack of the native microenvironment and clinical applicability.Main bodyThe concept of organoids has derived patient‐derived tumour organoids (PDTOs) for personalized drug screening and new drug discovery, mitigating the risks of medication misuse. The greater the similarity between the PDTOs and the primary tumours, the more influential the model will be. Recently, ‘tumour assembloids’ inspired by cell‐coculture technology have attracted attention to complement the current PDTO technology. High‐quality PDTOs must reassemble critical components, including multiple cell types, tumour matrix, paracrine factors, angiogenesis and microorganisms. This review begins with a brief overview of the history of organoids and PDTOs, followed by the current approaches for generating PDTOs and tumour assembloids. Personalized drug screening has been practised; however, it remains unclear whether PDTOs can predict immunotherapies, including immune drugs (e.g. immune checkpoint inhibitors) and immune cells (e.g. tumour‐infiltrating lymphocyte, T cell receptor‐engineered T cell and chimeric antigen receptor‐T cell). PDTOs, as cancer avatars of the patients, can be expanded and stored to form a biobank.ConclusionFundamental research and clinical trials are ongoing, and the intention is to use these models to replace animals. Pre‐clinical immunotherapy screening using PDTOs will be beneficial to cancer patients.Key Points The current PDTO models have not yet constructed key cellular and non‐cellular components. PDTOs should be expandable and editable. PDTOs are promising preclinical models for immunotherapy unless mature PDTOs can be established. PDTO biobanks with consensual standards are urgently needed.

show abstract

Section: Pdtos and Assembloidsmentioning

confidence: 99%

Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy

Mei,

Liu,

Tian

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…To be direct, 2D culture systems are unable to construct the architecture and microenvironment of the human tumour. 83…”

Section: Application Of Printable Biomaterials For Cancer Therapymentioning

confidence: 99%

“…114,115 This innovative approach involves creating patient-specific, biomimetic cancer models that closely mimic the unique characteristics of an individual's tumor. 83 The process begins with the procurement of primary cell lines or cells directly from a patient's tumor biopsy, ensuring a personalized cellular foundation. These cells are then integrated into a suitable biomaterial, chosen based on the specific bioprinting method employed.…”

Section: Application Of Printable Biomaterials For Cancer Therapymentioning

confidence: 99%

Application of 3D, 4D, 5D, and 6D bioprinting in cancer research: what does the future look like?

Khorsandi,

Rezayat,

Sezen

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Targeted Cancer Therapy‐on‐A‐Chip

Abed,

Radha,

Anjum

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Targeted cancer therapy (TCT) is gaining increased interest because it reduces the risks of adverse side effects by specifically treating tumor cells. TCT testing has traditionally been performed using two‐dimensional (2D) cell culture and animal studies. Organ‐on‐a‐chip (OoC) platforms have been developed to recapitulate cancer in vitro, as cancer‐on‐a‐chip (CoC), and used for chemotherapeutics development and testing. This review explores the use of CoCs to both develop and test TCTs, with a focus on three main aspects, the use of CoCs to identify target biomarkers for TCT development, the use of CoCs to test free, un‐encapsulated TCTs, and the use of CoCs to test encapsulated TCTs. Despite current challenges such as system scaling, and testing externally triggered TCTs, TCToC shows a promising future to serve as a supportive, pre‐clinical platform to expedite TCT development and bench‐to‐bedside translation.

show abstract

Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues

Cited by 13 publications

References 125 publications

Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy

Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy

Application of 3D, 4D, 5D, and 6D bioprinting in cancer research: what does the future look like?

Targeted Cancer Therapy‐on‐A‐Chip

Contact Info

Product

Resources

About